Global Neuronal Migration Disorder Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Neuronal Migration Disorder Treatment Market Overview

The Neuronal Migration Disorder Treatment Market was valued at USD 1.55 billion in 2025 and is projected to reach USD 2.97 billion by 2033, growing at a CAGR of 8.50% from 2026 to 2033. The Global Neuronal Migration Disorder (NMD) Treatment Market is experiencing steady growth driven by increasing awareness of rare neurological disorders, rising diagnosis rates due to advancements in genetic testing and neuroimaging technologies, and growing availability of supportive and symptomatic treatment approaches. The increasing prevalence of congenital brain malformations such as lissencephaly, polymicrogyria, and heterotopia is further contributing to demand for improved therapeutic and long-term management solutions.

The growing burden of pediatric neurological disorders globally, combined with expanding neonatal screening programs and improved access to specialized pediatric neurology care, is encouraging healthcare systems, hospitals, and research institutes to adopt advanced diagnostic and treatment strategies. While there is currently no curative therapy for most neuronal migration disorders, supportive treatments such as antiepileptic drugs, physical therapy, occupational therapy, and emerging gene-based research approaches are increasingly being utilized to manage symptoms and improve quality of life. Advances in precision medicine, rare disease research funding, and neurodevelopmental studies are further strengthening the development pipeline for targeted therapies in this market.

Key Market Trends & Insights

• North America dominated the Neuronal Migration Disorder Treatment Market with the largest revenue share of 38.62% in 2025, supported by advanced neurology care infrastructure, strong presence of specialized pediatric neurology centers, high diagnosis rates of rare neurological disorders, and robust reimbursement frameworks. The region also benefits from strong adoption of advanced antiepileptic therapies, genetic testing integration, and increasing R&D activities focused on rare brain malformations.
• The Antiepileptic Medication segment dominated the market with a 46.78% revenue share in 2025, due to its widespread use as first-line therapy for managing seizures associated with neuronal migration disorders such as lissencephaly and polymicrogyria. Continuous treatment regimens, long-term patient dependency, and availability of multiple drug classes including valproate, levetiracetam, and lamotrigine support segment dominance.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.4% from 2026 to 2033, fueled by improving healthcare infrastructure, rising awareness of rare neurological disorders, increasing newborn screening programs, and expanding access to pediatric neurology care in countries such as China, India, and Japan. Growing government support for rare disease diagnosis and increasing hospital investments are further accelerating regional market growth.
• The Supportive Care segment is expected to register the fastest CAGR of 7.9% from 2026 to 2033, driven by increasing adoption of multidisciplinary care approaches including physiotherapy, occupational therapy, speech therapy, and nutritional support. The chronic and non-curative nature of neuronal migration disorders is further increasing demand for long-term supportive management strategies.
• The Hospitals segment dominated the market with a 52.14% share in 2025, attributed to high patient inflow for neurological diagnosis, availability of advanced imaging (MRI, CT), access to pediatric intensive care units, and presence of specialized neurologists. Hospitals remain the primary point of diagnosis and long-term management for severe congenital brain malformations.
• The Homecare segment is expected to witness the fastest CAGR of 8.1% from 2026 to 2033, supported by rising demand for long-term supportive management outside hospital settings, increasing caregiver training programs, and growing adoption of remote monitoring for epilepsy and neurological symptom tracking in pediatric patients.
• The Hospital Pharmacy segment dominated the distribution channel with a 61.35% revenue share in 2025, driven by strong prescription control, high dependency on inpatient treatment pathways, and centralized procurement of antiepileptic and supportive medications within hospital systems.
• The Online Pharmacy segment is expected to grow at the fastest CAGR of 9.2% from 2026 to 2033, supported by increasing digital health adoption, improved access to chronic disease medications, rising e-prescription usage, and expanding tele-neurology consultation services across emerging economies.
• The Antiepileptic Medication segment dominated the market with a 62.18% share in 2025 due to the high prevalence of seizure disorders associated with neuronal migration abnormalities.

Market Size & Forecast

• Global Market Value (2025): USD 1.55 Billion
• Expected Market Value (2033): USD 2.97 Billion
• Forecast CAGR (2026–2033): 8.50%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Neuronal Migration Disorder Treatment Market Segmentation

Neuronal Migration Disorder Treatment Market Trends

Trend: Growth in Precision Neurology, Genetic Diagnosis & Multidisciplinary Care

The Neuronal Migration Disorder Treatment Market is witnessing a strong shift toward precision neurology, early genetic diagnosis, and integrated multidisciplinary care approaches. Advances in MRI imaging and next-generation sequencing have significantly improved detection rates of congenital cortical malformations such as lissencephaly, schizencephaly, and polymicrogyria. According to the National Organization for Rare Disorders (NORD), many neuronal migration disorders are now being diagnosed earlier in infancy due to improved neuroimaging accessibility and expanding newborn screening programs in developed regions.

Hospitals and specialty neurology centers are increasingly adopting AI-assisted neuroimaging tools to identify cortical development abnormalities at earlier stages. In parallel, increasing awareness of rare neurological diseases has led to higher diagnosis rates in pediatric populations, particularly in North America and Europe. Multidisciplinary treatment models combining neurology, physiotherapy, occupational therapy, and epilepsy management are becoming standard care pathways, especially for patients with severe developmental delay and drug-resistant seizures.

Neuronal Migration Disorder Treatment Market Dynamics

Key Market Driver: Rising Prevalence of Pediatric Epilepsy and Advances in Neurodiagnostic Technologies

The growing global burden of pediatric epilepsy and congenital brain malformations is a key driver of the neuronal migration disorder treatment market. The World Health Organization (WHO) estimates that neurological disorders affect over 1 billion people globally, with epilepsy alone impacting nearly 50 million individuals worldwide. A significant portion of severe childhood epilepsy cases is linked to structural brain abnormalities, including neuronal migration disorders.

Improved diagnostic capabilities such as high-resolution MRI, fetal imaging, and genetic testing (including whole-exome sequencing) are enabling earlier and more accurate identification of cortical malformations. Pharmaceutical companies are also expanding use of advanced antiepileptic drugs such as levetiracetam and lamotrigine, which remain first-line therapies for symptom management in these disorders. Increasing healthcare expenditure on rare neurological diseases in countries such as the U.S., Japan, and Germany is further accelerating market growth.

Key Restraint/Challenge: Lack of Curative Treatments and High Long-Term Care Burden

A major challenge in the Neuronal Migration Disorder Treatment Market is the absence of curative therapies, with current treatment largely limited to symptomatic management such as seizure control and supportive care. These disorders are caused by irreversible abnormalities in fetal brain development, making long-term management essential.

The economic burden is also significant, as patients often require lifelong care involving multiple therapies including neurology consultations, rehabilitation, and assistive support services. According to rare disease healthcare burden studies, families of children with severe neurodevelopmental disorders can incur substantially higher lifetime care costs compared to typical neurological conditions, especially in regions without strong insurance coverage or public healthcare support.

In addition, limited availability of specialized pediatric neurologists and advanced diagnostic infrastructure in low- and middle-income countries restricts early diagnosis and treatment access, contributing to underreporting and delayed intervention.

Key Market Opportunity: Expansion of Genetic Research, Orphan Drug Development & Advanced Neurotherapies

A major opportunity in this market lies in the expansion of genetic research and orphan drug development targeting rare cortical malformations. Pharmaceutical and biotech companies are increasingly investing in gene-based research to understand mutations affecting neuronal migration pathways such as LIS1 and DCX gene abnormalities, which are strongly associated with lissencephaly.

Global regulatory incentives such as the U.S. Orphan Drug Act and European Orphan Medicinal Product designation are encouraging drug development for rare neurological disorders. Companies are also exploring neuroprotective agents and targeted epilepsy therapies designed specifically for structural brain abnormalities.

In addition, increasing adoption of digital health platforms and tele-neurology services is improving long-term monitoring and care access for patients in remote regions. Countries such as India and China are expanding rare disease registries and national neurodevelopmental disorder programs, creating significant opportunities for diagnostic companies, pharmaceutical firms, and healthcare service providers.

Neuronal Migration Disorder Treatment Market Scope

The Neuronal Migration Disorder Treatment market is segmented on the basis of product, type, treatment type, route of administration, end-users, and distribution channel

• By Product

On the basis of product, the Neuronal Migration Disorder Treatment Market is segmented into Neurostimulation Devices and Cerebrospinal Fluid Devices. The Neurostimulation Devices segment dominated the market with a 57.84% share in 2025 due to its increasing adoption in managing neurological dysfunctions associated with neuronal migration disorders. These devices help regulate abnormal brain activity, reduce seizure frequency, and improve neurological outcomes in affected patients. Growing clinical preference for non-invasive and minimally invasive neuromodulation techniques is strengthening demand. Rising prevalence of epilepsy linked to neuronal migration disorders further supports market dominance. Increasing hospital adoption of advanced neurostimulation technologies is driving segment expansion. Strong clinical evidence supporting efficacy enhances physician confidence. Continuous technological advancements in implantable and external stimulation systems are improving treatment precision. Rising healthcare expenditure on neurological disorders further reinforces adoption. Government and institutional support for neurological care programs is also contributing to growth. Overall, neurostimulation remains the most widely adopted therapeutic product segment.

The Cerebrospinal Fluid Devices segment is expected to witness the fastest growth at a CAGR of 8.2% from 2026 to 2033, driven by increasing utilization in managing complications associated with neuronal migration disorders such as hydrocephalus. These devices help regulate cerebrospinal fluid flow and reduce intracranial pressure, improving neurological stability. Rising incidence of congenital brain malformations is fueling demand. Advancements in shunt systems and programmable valves are enhancing treatment outcomes. Increasing pediatric neurological cases are further driving adoption. Growing awareness among healthcare providers supports early intervention. Expansion of neurosurgical infrastructure in emerging economies is accelerating growth. Technological innovation in biocompatible materials is improving device safety. Rising hospital investments in neurosurgical equipment further strengthen adoption. Overall, this segment is emerging as a high-growth therapeutic device category.

• By Type

On the basis of type, the Neuronal Migration Disorder Treatment Market is segmented into Lissencephaly, Schizencephaly, and Porencephaly. The Lissencephaly segment dominated the market with a 44.36% share in 2025 due to its higher prevalence and severe neurological manifestations requiring long-term treatment and management. Lissencephaly patients often require continuous medical intervention including seizure control, supportive therapy, and neurodevelopmental care. Increasing diagnosis rates through advanced neuroimaging techniques are supporting early identification. Strong clinical focus on pediatric neurology is driving treatment demand. Hospitals and specialty neurological centers are heavily involved in managing these cases. Growing awareness of rare neurological disorders further strengthens diagnosis rates. Multidisciplinary treatment approaches are enhancing patient outcomes. Government rare disease programs are also supporting treatment accessibility. Rising genetic screening adoption is improving early detection. Overall, Lissencephaly remains the most clinically significant segment.

The Schizencephaly segment is expected to witness the fastest growth at a CAGR of 8.5% from 2026 to 2033 due to increasing diagnosis rates and improved neuroimaging capabilities. Rising awareness among neurologists regarding structural brain abnormalities is contributing to higher detection. Advancements in MRI and prenatal screening technologies are enabling early identification. Increasing pediatric neurological consultations are driving treatment adoption. Growth in supportive care therapies is improving survival outcomes. Expanding healthcare infrastructure in developing countries is further accelerating diagnosis. Rising genetic counseling services are supporting early intervention. Increasing clinical research in cortical malformations is boosting awareness. Improved treatment pathways for developmental delay conditions are enhancing demand. Overall, this segment shows strong future expansion potential.

• By Treatment Type

On the basis of treatment type, the market is segmented into Antiepileptic Medication and Supportive Care. The Antiepileptic Medication segment dominated the market with a 62.18% share in 2025 due to the high prevalence of seizure disorders associated with neuronal migration abnormalities. These medications are widely used to control epilepsy symptoms, which are the most common clinical manifestation. Strong clinical guidelines recommending antiepileptic drugs for symptom management reinforce adoption. Increasing availability of advanced second-generation antiepileptic drugs is improving treatment outcomes. Hospitals and neurology clinics rely heavily on pharmacological management. Growing pediatric epilepsy cases further support demand. Improved drug accessibility in both developed and emerging regions is strengthening market penetration. Continuous innovation in targeted neurological therapies is enhancing effectiveness. Rising healthcare awareness and early diagnosis are also contributing to growth. Overall, medication-based treatment remains the cornerstone of disease management.

The Supportive Care segment is expected to witness the fastest growth at a CAGR of 7.9% from 2026 to 2033 due to increasing demand for multidisciplinary care approaches. Supportive therapies include physiotherapy, occupational therapy, speech therapy, and developmental care interventions. These treatments significantly improve quality of life in patients with neuronal migration disorders. Rising awareness of holistic neurological care is driving adoption. Increasing involvement of rehabilitation centers is supporting segment expansion. Growth in homecare services is further boosting demand. Early intervention programs in pediatric neurology are enhancing treatment outcomes. Government healthcare initiatives are promoting supportive care integration. Expanding insurance coverage for rehabilitation therapies is improving accessibility. Overall, supportive care is becoming an essential component of long-term treatment strategies.

• By Route of Administration

On the basis of route of administration, the market is segmented into Parenteral and Intravenous routes. The Intravenous segment dominated the market with a 55.73% share in 2025 due to its rapid drug delivery efficiency and effectiveness in acute neurological symptom management. Intravenous administration ensures immediate therapeutic response, which is critical in seizure and neurological crisis management. Hospitals widely prefer IV administration for controlled dosing. Strong adoption in emergency care settings further supports dominance. Availability of hospital-based infusion infrastructure enhances usage. Increasing use in pediatric neurological treatments is also contributing to growth. Improved drug formulations compatible with IV delivery are strengthening adoption. Clinical preference for fast-acting treatments supports segment leadership. High patient inflow in hospital neurology departments further reinforces demand. Overall, intravenous administration remains the preferred clinical route.

The Parenteral segment is expected to witness the fastest growth at a CAGR of 7.6% from 2026 to 2033 due to increasing use in long-term neurological management therapies. Parenteral administration offers sustained drug delivery and improved bioavailability. Rising adoption of injectable formulations for chronic neurological care is driving demand. Growth in home-based care and outpatient treatment is supporting usage. Technological advancements in drug delivery systems are improving safety and convenience. Increasing preference for minimally invasive treatment options is boosting adoption. Expanding availability of self-administration therapies is further supporting growth. Improved patient compliance with parenteral therapies enhances effectiveness. Rising neurological disorder prevalence is fueling long-term treatment needs. Overall, parenteral administration is emerging as a growing therapeutic route.

• By End-Users

On the basis of end-users, the market is segmented into Hospitals, Homecare, Specialty Centers, and Others. The Hospitals segment dominated the market with a 61.49% share in 2025 due to the availability of advanced neurological care infrastructure and specialized treatment facilities. Hospitals serve as primary centers for diagnosis, treatment, and long-term management of neuronal migration disorders. High patient inflow and access to multidisciplinary teams support dominance. Advanced diagnostic imaging and neurosurgical capabilities further strengthen hospital preference. Strong reimbursement systems improve treatment accessibility. Increasing pediatric neurology cases are primarily managed in hospitals. Availability of emergency care and intensive monitoring enhances treatment outcomes. Government healthcare support for neurological disorders further reinforces adoption. Integration of advanced therapeutic devices also supports hospital usage. Overall, hospitals remain the central treatment hub.

The Specialty Centers segment is expected to witness the fastest growth at a CAGR of 8.3% from 2026 to 2033 due to rising demand for focused neurological care. These centers provide specialized treatment for rare and complex brain disorders. Increasing number of neurology-focused clinics is driving expansion. Advanced rehabilitation and diagnostic capabilities enhance patient outcomes. Growing preference for outpatient specialty care supports adoption. Rising awareness of early neurological intervention is boosting demand. Expansion of private healthcare infrastructure further supports growth. Integration of advanced neurotherapeutic technologies is improving efficiency. Increasing referral cases from general hospitals strengthen patient inflow. Overall, specialty centers are emerging as a rapidly expanding segment.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy segment dominated the market with a 64.27% share in 2025 due to direct access to prescription-based neurological treatments and strong integration with inpatient care systems. Hospital pharmacies ensure immediate availability of critical medications for neurological disorders. Strong regulatory control over prescription drugs supports dominance. High dependence on hospital-based treatment pathways further strengthens usage. Availability of specialized neurological drugs is concentrated in hospitals. Increasing inpatient admissions for neurological conditions supports demand. Government healthcare procurement systems favor hospital distribution channels. Integration with hospital electronic medical systems improves efficiency. Strong supply chain networks ensure consistent drug availability. Overall, hospital pharmacies remain the primary distribution channel.

The Online Pharmacy segment is expected to witness the fastest growth at a CAGR of 9.1% from 2026 to 2033 due to increasing digital healthcare adoption and rising demand for convenient medication access. Growing internet penetration and smartphone usage are driving online pharmacy expansion. Patients increasingly prefer home delivery of chronic neurological medications. Expansion of e-prescription systems supports growth. Improved regulatory frameworks for online drug sales enhance trust. Rising telemedicine adoption is further boosting demand. Increasing availability of rare neurological disorder drugs online supports accessibility. Cost-effective pricing models are attracting patients. Digital health platforms are integrating pharmacy services for convenience. Overall, online pharmacies represent the fastest-growing distribution channel.

Neuronal Migration Disorder Treatment Market Regional Analysis

North America dominated the Neuronal Migration Disorder Treatment market and accounted for the largest revenue share of 38.62% in 2025, supported by advanced neurology care infrastructure, strong presence of specialized pediatric neurology centers, high diagnosis rates of rare neurological disorders, and robust reimbursement frameworks. The region also benefits from strong adoption of advanced antiepileptic therapies, genetic testing integration, and increasing R&D activities focused on rare cortical brain malformations such as lissencephaly and polymicrogyria. Increasing focus on precision medicine, early diagnosis through MRI and genomic screening, and strong orphan drug availability continues to strengthen North America’s leadership position in the global market.

U.S. Neuronal Migration Disorder Treatment Market Insight

The U.S. Neuronal Migration Disorder Treatment market is witnessing strong growth due to rising investments in rare disease diagnosis programs, advanced neuroimaging technologies, and expanding genetic testing adoption. The country’s well-established healthcare infrastructure, along with strong presence of leading pharmaceutical and biotechnology companies, is driving demand across hospitals, specialty neurology centers, and research institutions. In addition, increasing focus on early childhood epilepsy management and precision medicine approaches is accelerating treatment adoption across the country.

Europe Neuronal Migration Disorder Treatment Market Insight

The Europe Neuronal Migration Disorder Treatment market remains a major contributor to global revenue, driven by strong healthcare systems, government support for rare disease programs, and advanced neurological research capabilities. Widespread adoption of antiepileptic therapies, improved access to diagnostic imaging, and increasing investment in orphan drug development are supporting market expansion across the region. In addition, strong collaboration between academic research centers and pharmaceutical companies continues to enhance innovation in treatment approaches.

U.K. Neuronal Migration Disorder Treatment Market Insight

The U.K. Neuronal Migration Disorder Treatment market is experiencing steady growth, supported by increasing awareness of rare neurological conditions, strong NHS-backed diagnostic frameworks, and rising investment in pediatric neurology services. Growing adoption of genetic testing and advanced MRI-based diagnosis is improving early detection rates. Furthermore, expansion of specialized epilepsy centers and increasing focus on long-term supportive care are contributing to market growth.

Germany Neuronal Migration Disorder Treatment Market Insight

The Germany Neuronal Migration Disorder Treatment market is expanding steadily due to strong clinical research infrastructure, high healthcare expenditure, and advanced neurological care facilities. Hospitals and research institutes are increasingly adopting genomic testing and precision neurology approaches for early diagnosis and treatment planning. Continuous investment in rare disease research and strong pharmaceutical manufacturing capabilities are further driving market development.

Asia-Pacific Neuronal Migration Disorder Treatment Market Insight

The Asia-Pacific Neuronal Migration Disorder Treatment market is expected to witness rapid growth, driven by improving healthcare infrastructure, rising awareness of rare neurological disorders, and increasing access to pediatric neurology services. Countries such as China, India, and Japan are expanding newborn screening programs and genetic testing capabilities. In addition, growing government support for rare disease diagnosis and increasing availability of affordable antiepileptic medications are accelerating regional market growth.

Japan Neuronal Migration Disorder Treatment Market Insight

The Japan Neuronal Migration Disorder Treatment market is witnessing consistent growth due to advanced healthcare infrastructure, strong focus on rare neurological disease research, and high adoption of early diagnostic technologies. Increasing use of MRI-based neuroimaging and genetic screening is improving detection rates. Moreover, strong government support for rare disease management and well-established pediatric neurology networks are contributing to market expansion.

China Neuronal Migration Disorder Treatment Market Insight

The China Neuronal Migration Disorder Treatment market is growing rapidly, driven by expanding healthcare infrastructure, rising awareness of rare neurological conditions, and increasing government investment in rare disease programs. Growing adoption of genetic testing, improved access to pediatric neurology care, and expansion of tertiary hospitals are significantly supporting market growth. In addition, increasing focus on early diagnosis and affordable treatment access is positioning China as a key emerging market globally.

Neuronal Migration Disorder Treatment Market Share

The Neuronal Migration Disorder Treatment industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Sanofi S.A. (France)
• Roche Holding AG (Switzerland)
• Johnson & Johnson (U.S.)
• GlaxoSmithKline plc (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Eisai Co., Ltd. (Japan)
• UCB S.A. (Belgium)
• Sumitomo Pharma Co., Ltd. (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Viatris Inc. (U.S.)
• AbbVie Inc. (U.S.)
• AstraZeneca plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Bristol Myers Squibb (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Lupin Limited (India)
• H. Lundbeck A/S (Denmark)
• Sandoz Group AG (Switzerland)
• Jazz Pharmaceuticals plc (Ireland)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Bayer AG (Germany)
• Amgen Inc. (U.S.)
• Biogen Inc. (U.S.)
• CSL Limited (Australia)
• Hikma Pharmaceuticals PLC (U.K.)
• Eisai Pharmaceuticals India (India)
• Torrent Pharmaceuticals Ltd. (India)

Latest Developments in Neuronal Migration Disorder Treatment Market

• In March 2023, the European Medicines Agency (EMA) approved leniolisib (Joenja) developed by Pharming Group, marking the first targeted therapy for activated PI3K-delta syndrome (APDS), a rare genetic immunological disorder with neurological manifestations. The approval highlighted growing regulatory support for precision therapies in rare neurodevelopmental and immune-related disorders. This milestone strengthened the broader rare neurological disease treatment landscape by validating pathway-specific drug development approaches
• In December 2024, Ionis Pharmaceuticals received U.S. FDA approval for Tryngolza (olezarsen), an RNA-targeted therapy for familial chylomicronemia syndrome (FCS), a rare genetic metabolic disorder linked with severe neurological and systemic complications. The approval demonstrated increasing adoption of nucleic-acid-based therapies for rare neurological and genetic conditions, expanding treatment innovation in ultra-rare disease segments
• In October 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Wainua (eplontersen), developed by Ionis and AstraZeneca, for hereditary transthyretin-mediated amyloidosis. The therapy received EU marketing authorization in March 2025, expanding the use of RNA-targeted treatments for rare neurodegenerative and neuropathic conditions. This approval reinforced the rapid growth of RNA-based neurological therapeutics
• In April 2024, Roche reported extended Phase II clinical data from the PASADENA study of prasinezumab, an investigational α-synuclein antibody for early-stage Parkinson’s disease. The results showed sustained potential benefits on motor progression, supporting continued clinical development in neurodegenerative disease pathways relevant to neuronal dysfunction and migration-related neurological research
• In June 2025, Genentech (Roche Group) announced advancement of prasinezumab into Phase III clinical trials for early-stage Parkinson’s disease following encouraging Phase II results. This marked a significant step in developing disease-modifying therapies targeting neurodegeneration, reinforcing pharmaceutical investment in CNS-targeted biologics
• In February 2025, Praxis Precision Medicines reported successful Phase III results for ulixacaltamide in essential tremor, achieving statistically significant improvement in patient outcomes. The study demonstrated the increasing success of CNS-targeted small molecules for rare neurological disorders and supported further regulatory submissions in 2026

SKU-60446